What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Some antibiotic combinations have a sound clinical purpose, but putting multiple antibiotics into one fixed-dose product does not make it effective or appropriate. A 2018 report on a study of products sold in India said 75 of 118 antibiotic fixed-dose combinations examined had not been approved. That is a historical study-period finding—not a current count, proof that every combination is harmful, or evidence that the products measured caused a specific increase in antimicrobial resistance.
What are fixed-dose combination drugs?
A fixed-dose combination (FDC) contains two or more active ingredients in a single formulation, such as one tablet. The ingredients are supplied together in set proportions, rather than as separate medicines whose doses can be adjusted independently.
FDCs are not inherently unsafe or irrational. A combination may be justified when each ingredient contributes to treatment and the formulation has evidence supporting its intended use. The key question is not how many ingredients it contains, but whether the specific product, doses and clinical purpose are supported.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →What makes an antibiotic FDC “irrational”?
An antibiotic FDC is scientifically unsupported or irrational when its ingredients, dose ratio or intended use lack an adequate therapeutic rationale or evidence of benefit. Regulatory approval is a separate but important question: a product’s legal status depends on the specific formulation and jurisdiction, and it can change over time.
#1 Best Overall
To assess a particular combination, relevant questions include:
- Is that exact product approved in the jurisdiction where it is being used?
- Is there evidence that each antibiotic contributes to the intended clinical benefit?
- Does the combination offer a meaningful advantage over an appropriate alternative?
- Are the ingredients’ safety profiles and potential interactions understood?
- Do their dosing schedules fit together?
- Would the fixed ratio prevent a clinician from adjusting one ingredient without changing the other?
These are product-specific questions. A general warning about unsupported combinations cannot establish whether a particular prescription is appropriate.
What did the 2018 India report find?
In a 17 February 2018 report, Chemistry World described research by P. McGettigan and colleagues on antibiotic FDCs sold in India. The report said that 75 of 118 combinations examined had not been approved. It also noted that many of the formulations lacked publicly available safety and efficacy data.
Rank #2
- Storey publishing
- Language: english
- Book - herbal antibiotics, 2nd edition: natural alternatives for treating drug-resistant bacteria
The figure describes the products and regulatory situation examined in that study period. It should not be read as the current number of unapproved products, as a claim that all antibiotic FDCs in India were illegal, or as a product-by-product assessment of combinations available today. The report described government efforts to outlaw many combinations and said the ban was being litigated at the time. It cited a paper in the British Journal of Clinical Pharmacology (2018; DOI 10.1111/bcp.13503), but the paper itself is not independently assessed here.
The report also quoted Allyson Pollock, a study co-author: “Patients are consuming medicines that are potentially harmful.” That is a warning about possible risk, not proof that every combination caused harm.
How could unsupported combinations contribute to antimicrobial resistance?
Antibiotics expose bacteria to selection pressure: susceptible bacteria may be eliminated while bacteria with resistance traits survive and multiply. Unnecessary or prolonged antibiotic use can increase that exposure. When a product adds an antibiotic without a demonstrated benefit, it may therefore add avoidable pressure on bacteria.
Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy, described the concern in the 2018 Chemistry World report: “We are generating multidrug resistance to unrelated antibiotics very rapidly because the same bug is seeing extraordinary selection pressure from two antibiotics.” This expresses a stewardship concern about exposure to multiple antibiotics; it does not establish that every FDC causes resistance.
Free tools Windows power users keep installed
One-click scans. No signup required.
The reporting available for the 2018 study does not quantify a causal effect of the examined formulations on resistance or show that a specific product produced a measured resistance outcome. The defensible point is narrower: unsupported or unnecessary antibiotic exposure is a plausible source of additional selection pressure, which is one reason to use antibiotics only when clinically justified.
What other risks are associated with irrational FDC use?
Reported concerns include adverse effects, allergic reactions, possible interactions and difficulty changing the dose of one component without changing the other. A fixed formulation can also make it harder to match treatment to a patient’s needs if the ingredients have different dosing schedules or one is unnecessary. These are potential concerns, not findings that every FDC produces those outcomes.
Rank #4
The 2018 report said many formulations lacked publicly available safety and efficacy data. Lack of publicly available data is not by itself proof that a product is harmful, but it makes it harder for clinicians and patients to assess whether the combination’s benefits and risks are established.
Marc Mendelson was quoted in that report saying most bacterial infections can be treated with one antibiotic and a second is often redundant. This is an attributed general observation, not a universal prescribing rule: some combination regimens do have established clinical uses. Whether multiple antibiotics are justified depends on the infection and the specific treatment evidence.
Recommended Free Tools
What does the later rural India survey add?
A 2022 cross-sectional study in Antibiotics surveyed 196 informal providers in rural India. It reported that 21% of the sampled providers stocked antibiotic combinations and 46% stocked combinations that WHO does not recommend. Those percentages describe the surveyed providers, not the national prevalence of combination use or the share of all Indian providers selling such products.
The study also described difficulties in studying informal markets, including the lack of sampling frames, sales or patient records, and reluctance to disclose illegal sales. Its results provide context about the sampled sites, but they do not resolve the legal status or clinical quality of every product in India.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What is known about current regulatory status?
Regulatory status must be checked for the specific product and jurisdiction. A 4 July 2026 Indian Express explainer reported that the government had banned 16 FDC drugs, including certain antibiotic combinations. That is secondary reporting; the official order and product list, as well as any relevant court proceedings, are not established here. The report should not be treated as a complete or independently verified account of the current legal position.
The Central Drugs Standard Control Organization’s public notices listing includes a notice dated 5 September 2026 about coordinated action against illegal manufacture and distribution of misbranded drugs. That notice is not specific to antibiotic FDCs and does not settle the status of the combinations discussed in the 2018 report.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Patricia McGettigan, a study co-author, told Chemistry World: “When you speak to clinicians [in India] about fixed dose combinations, they say they are a terrible idea.” This is her account of clinicians she spoke to, not a survey establishing professional consensus.
What should patients and clinicians take from the concern?
- For patients: Do not start, stop, combine or change antibiotic doses on your own. Ask the prescriber or pharmacist what each ingredient is for and whether the exact product is appropriate for your treatment.
- For prescribers: Assess the evidence and regulatory status for the exact formulation, and consider whether each component is needed and whether the fixed doses allow appropriate adjustment.
- For readers checking a legal claim: Look for the current official product-specific order and relevant court decisions. A past study finding or a news report about a ban does not establish today’s status of every product.
The central distinction is between combinations with a supported therapeutic role and products whose benefit or rationale is not established. Concern about the latter is warranted because unnecessary antibiotic exposure can add selection pressure and because fixed formulations may complicate safety and dosing—but the evidence cited here does not show that every combination is harmful or that the 2018 study measured a resistance effect.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
